{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '9', 'ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT', 'Two types of asthma exacerbation are defined in this study, as outlined below:', '1)', 'A severe exacerbation event during the study is defined as a deterioration of asthma requiring:', 'Use of systemic corticosteroids for >3 days; or', 'Hospitalization or emergency room visit because of asthma, requiring systemic', 'corticosteroids', '2) A LOAC event is defined as any of the following:', '>6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a', '24 hour period (compared to baseline) on 2 consecutive days;', 'Increase in ICS dose >4 times than the dose at Visit 2;', 'A decrease in AM or PM peak flow of 30% or more on 2 consecutive days of treatment,', 'based on the defined stability limit. The Treatment Period stability limit is defined as the', 'respective mean AM or PM peak expiratory flow obtained over the last 7 days prior to', 'randomization (Day1);', 'Severe exacerbation event', 'Two events will be considered as different if the interval between their start dates is equal or', 'greater than 28 days.', 'The reasons (eg, infections including viral and bacterial, allergen exposure, exercise and others)', 'for any exacerbation event will be recorded in the e-CRF.', '9.1', 'PRIMARY ENDPOINT', 'The primary endpoint for this study is:', 'Annualized rate of severe exacerbation events during the 52-week placebo-controlled', 'treatment period.', '9.2', 'SECONDARY ENDPOINTS', '9.2.1 Key Secondary Efficacy Enppoint', 'Change from Baseline in pre-bronchodilator % predicted FEV1 at Week 12.', '9.2.2 Secondary Efficacy Enpoints', 'Change from Baseline in pre-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 24, 36,', 'and 52 and other time points assessed.', 'Time to first severe exacerbation event during 52-week treatment period.', 'Time to first LOAC Event during 52-week treatment period.', 'Property of the Sanofi Group - strictly confidential', 'Page 59', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Change from Baseline in other lung function measurements (absolute and relative FEV1,', 'AM/PM peak expiratory flow, FVC, forced expiratory flow (FEF) 25-75%,', 'post-bronchodilator % predicted FEV1) at Weeks 2, 4, 8, 12, 24, 36, 52, and other time', 'points assessed.', 'The effect of dupilumab on healthcare resource utilization (HCRU)', 'Change from Baseline at Weeks 2, 4, 8, 12, 24, 36, and 52 and other timepoints in:', '-', 'Morning/evening asthma symptom score (electronic diary)', '- PRO:', 'ACQ-IA, for children 6 to <12 years old,', '-', 'Use of reliever medication', '-', 'Number of nocturnal awakenings due to asthma symptoms requiring the use of reliever', 'medication', 'Change from Baseline at Weeks 12, 24, 36, 52, 64 in:', '-', 'PRO:', 'Paediatric Asthma Quality of Life Questionnaire with Standardised Activities-', 'Interviewer Administered (PAQLQ(S)-IA) score, for children >7 to <12 years old', 'at Randomization Visit 2.', '9.2.2.1 Disease-specific Efficacy Measures', '9.2.2.1.1.1 Spirometry', 'A spirometer that meets the 2005 American Thoracic Society (ATS)/European Respiratory', 'Society (ERS) recommendations will be used. Spirometry should be performed in accordance', 'with the ATS/ ERS guidelines (8). For pre-bronchodilator measured parameters, including FEV1,', 'peak expiratory flow (PEF), FVC and FEF 25-75%, spirometry will be performed after a wash out', 'period of bronchodilators according to their action duration, for example, withholding the last', 'dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at least', '24 hours. This will be verified before performing the PEF measurements.', 'For post-bronchodilator FEV1, the measure should follow the steps as that at screening test for', 'reversibility validation.', 'At all visits, spirometry will be performed either in the AM or PM, but preferred in the AM, and', 'the spirometry should be done at approximately the same time at each visit throughout the study.', 'The same spirometer and standard spirometric techniques, including calibration, will be used to', 'perform spirometry at all visits and, whenever possible, the same person should perform the', 'measurements.', 'Property of the Sanofi Group - strictly confidential', 'Page 60', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}